GlassScriptPhysician profile
Darcie C Mcdonaugh
NPI 1730578964
$47,031.44
in general payments reported to CMS, 2019-2025
25 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,165 · 2022: $2,873 · 2023: $2,785 · 2024: $17K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Food and Beverage: $5,871 · Travel and Lodging: $1,298 · Education: $13.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,810.00 |
| Food and Beverage | $5,870.92 |
| Travel and Lodging | $1,298.35 |
| Education | $13.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $40,094.59 | 2021-2025 | Xeomin |
| Viiv Healthcare Company | $1,482.09 | 2021-2023 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $1,239.84 | 2021-2023 | |
| Abbvie INC. | $1,032.66 | 2021-2025 | |
| Galderma Laboratories, L.P. | $657.64 | 2021-2025 | |
| Allergan, INC. | $418.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $393.41 | 2021-2023 | Delstrigo, Pifeltro |
| Janssen Biotech, INC. | $379.67 | 2021-2023 | Symtuza |
| Revance Therapeutics, INC. | $306.83 | 2025 | Daxxify |
| Novo Nordisk INC | $221.82 | 2022 | |
| Theratechnologies INC. | $123.99 | 2023 | Egrifta, Trogarzo |
| Takeda Pharmaceuticals U.S.A., INC. | $117.38 | 2022-2023 | Trintellix |
| Antares Pharma, INC. | $103.31 | 2021-2022 | |
| Napo Pharmaceuticals INC | $101.80 | 2021-2023 | Mytesi |
| Glaxosmithkline, LLC. | $98.16 | 2021-2025 | Bexsero, Shingrix, Pediarix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72.98 | 2023 | Symtuza |
| Teva Pharmaceuticals USA, INC. | $41.37 | 2023 | Austedo Xr |
| Dynavax Technologies Corporation | $24.14 | 2022 | |
| Amarin Pharma, INC. | $21.36 | 2021 | |
| Indivior INC. | $19.57 | 2024 | Sublocade |
| Coopersurgical, INC. | $16.96 | 2023 | Paragard T 380a |
| Pfizer INC. | $16.89 | 2023 | |
| Emd Serono, INC. | $16.81 | 2022 | |
| Lilly USA, LLC | $15.17 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darcie Mcdonaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.